Hopp til innhold
NHI.no
Annonse

Ketamin ved depresjon: Behandlingsopplegget

Innhold i artikkelen

Behandlingsoppleggene varierer. Et eksempel er to infusjoner per uke i 3 uker, deretter 1 infusjon i 2 til 4 uker12. De fleste stanser behandlingen etter 6 uker. Den intravenøse infusjonen varer ca. 40 minutter. Den dissosiative opplevelsen starter raskt, og det tar omtrent 15 til 20 minutter før den avtar og opphører etter at dryppet er slutt. Lege og helsepersonell er tilgjengelig under hele prosessen. Behandlingen kombineres med etterfølgende samtaleterapi.

Annonse

De vanligste uønskede bivirkningene er dissosiasjon, kvalme, endret smakssans og svimmelhet. Disse opptrer kort tid etter dosering og går over etter omtrent en og en halv time.

For cirka 30 prosent holder det med én kur. Uker, måneder eller år etter den første behandlingskuren med 6 til 8 doser kan pasienten eventuelt komme tilbake for en påfyllingsdose - i noen tilfeller flere ganger.

  1. Jelen LA, Stone JM. Ketamine for depression. Int Rev Psychiatry. 2021;33(3):207-228. doi:10.1080/09540261.2020.1854194 DOI
  2. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251 DOI
  3. Swainson J, McGirr A, Blier P, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur published correction appears in Can J Psychiatry. 2021 Dec;66(12):1102. Can J Psychiatry. 2021;66(2):113-125. doi:10.1177/0706743720970860 DOI
  4. Kvam T-M, Stewart LH, Wahl A, Andreassen OA. Ketamin ved depresjon – evidens og forslag til praksis. Tidsskrift Nor Legeforen 2021. doi: 10.4045/tidsskr.21.0480 DOI
  5. Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019;13:3051-3067. Published 2019 Aug 27. doi:10.2147/DDDT.S221437 DOI
  6. Sykehuset Østfold. Ketamin mot behandlingsresistent depresjon. Sist oppdatert 24.03.2022. sykehuset-ostfold.no
  7. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. doi:10.1016/S0140-6736(17)32802-7 DOI
  8. Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23(8):627-647. doi:10.2165/00023210-200923080-00001 DOI
  9. Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord. 2020;263:568-575. doi:10.1016/j.jad.2019.11.028 DOI
  10. Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials published correction appears in Aust N Z J Psychiatry. 2020 Jul;54(7):766. Aust N Z J Psychiatry. 2020;54(1):29-45. doi:10.1177/0004867419883341 DOI
  11. Alnefeesi Y, Chen-Li D, Krane E, et al. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. J Psychiatr Res. 2022;151:693-709. doi:10.1016/j.jpsychires.2022.04.037 DOI
  12. Collins S, Brennan D. Ketamine for Depression: What to Know. WebMD. Last reviewed May 04, 2022. www.webmd.com
  13. Williams NR, Heifets BD, Blasey C, et al. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. Am J Psychiatry. 2018;175(12):1205-1215. doi:10.1176/appi.ajp.2018.18020138 DOI
  14. Hamby C. A Fraught New Frontier in Telehealth: Ketamine. The New York Times. Published Feb 20, 2023. www.nytimes.com
  15. Kaliora SC, Zervas IM, Papadimitriou GN. Electroconvulsive therapy: 80 years of use in psychiatry. 2018;29(4):291-302. doi:10.22365/jpsych.2018.294.291 DOI
  16. Menon V, Varadharajan N, Faheem A, Andrade C. Ketamine vs Electroconvulsive Therapy for Major Depressive Episode: A Systematic Review and Meta-analysis published online ahead of print, 2023 Apr 12. JAMA Psychiatry. 2023;e230562. doi:10.1001/jamapsychiatry.2023.0562 DOI
  17. Sepulveda Ramos C, Thornburg M, Long K, et al. The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review. Cureus. 2022;14(3):e23647. Published 2022 Mar 30. doi:10.7759/cureus.23647 DOI
  18. Highland JN, Zanos P, Riggs LM, et al. Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. Pharmacol Rev. 2021;73(2):763-791. doi:10.1124/pharmrev.120.000149 DOI
Annonse
Annonse